Sensei Biotherapeutics (NASDAQ:SNSE – Get Free Report) and CervoMed (NASDAQ:CRVO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Valuation & Earnings
This table compares Sensei Biotherapeutics and CervoMed”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sensei Biotherapeutics | N/A | N/A | -$34.10 million | ($1.20) | -0.31 |
| CervoMed | $7.14 million | 10.35 | -$2.17 million | ($2.03) | -4.18 |
CervoMed has higher revenue and earnings than Sensei Biotherapeutics. CervoMed is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Profitability
This table compares Sensei Biotherapeutics and CervoMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sensei Biotherapeutics | N/A | -53.86% | -46.91% |
| CervoMed | -118.68% | -44.11% | -39.81% |
Analyst Ratings
This is a summary of current ratings and price targets for Sensei Biotherapeutics and CervoMed, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sensei Biotherapeutics | 0 | 0 | 4 | 0 | 3.00 |
| CervoMed | 1 | 1 | 5 | 2 | 2.89 |
Sensei Biotherapeutics currently has a consensus target price of $4.25, indicating a potential upside of 1,049.58%. CervoMed has a consensus target price of $27.50, indicating a potential upside of 223.91%. Given Sensei Biotherapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Sensei Biotherapeutics is more favorable than CervoMed.
Institutional & Insider Ownership
10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 25.1% of CervoMed shares are held by institutional investors. 22.0% of Sensei Biotherapeutics shares are held by company insiders. Comparatively, 36.3% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
CervoMed beats Sensei Biotherapeutics on 8 of the 13 factors compared between the two stocks.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
About CervoMed
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
